Geneva, Aug. 6 -- International Clinical Trials Registry received information related to the study (NCT07725380) titled 'Domatinostat With Sirolimus for Relapsed, Refractory Sarcoma and Osteosarcoma' on July 21.
Study Type: Interventional
Study Design:
Allocation: Non-Randomized. Intervention model: Sequential Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Condition:
Sarcoma
Osteosarcoma
Intervention:
Drug: Domatinostat
Recruitment Status: Recruiting
Phase: Phase 1/Phase 2
Date of First Enrollment: July 15, 2026
Target Sample Size: 74
Countries of Recruitment:
United States
To know more, visit https://clinicaltrials.gov/study/NCT077...